IO Biotech reported mixed financial results for Q3 2025, with a significant decrease in operating expenses but a continued net loss. The company's lead drug candidate, Cylembio, narrowly missed its primary endpoint in a Phase 3 trial for advanced melanoma, though management views the results as de-risking. The company is planning discussions with the FDA for a new Phase 3 trial design.
Total operating expenses decreased by 27% to $19.4 million in Q3 2025 compared to $26.5 million in Q3 2024.
positiveResearch and development expenses decreased by 32% to $13.7 million in Q3 2025 compared to $20.2 million in Q3 2024.
positiveGeneral and administrative expenses decreased by 11% to $5.6 million in Q3 2025 compared to $6.3 million in Q3 2024.
positivePre-clinical data for additional T-win platform pipeline candidates (IO112 and IO170) were presented at SITC.
neutralThe Phase 3 pivotal trial (IOB-013) for Cylembio in advanced melanoma narrowly missed the primary PFS endpoint, despite demonstrating clinically relevant improvements in PFS and across virtually all subgroups.
attentionNet loss for Q3 2025 was $8.4 million, or $0.13 per share, compared to a net loss of $24.0 million, or $0.36 per share, in Q3 2024. While the loss narrowed, the company continues to incur significant losses.
negativeCash and cash equivalents decreased to $30.7 million as of September 30, 2025, from $60.0 million at December 31, 2024.
negativeThe company expects its current cash balance to support operations only through the first quarter of 2026.
negativeTotal liabilities increased significantly to $39.0 million as of September 30, 2025, from $20.7 million as of December 31, 2024, primarily due to new term loan debt and common stock warrants.
negativeMargin metrics will be available once backend extracts data from insights_json
The IOB-013 study results support the mechanism of action of our therapeutic cancer vaccines and, we believe, have significantly de-risked the program.
We look forward to discussing the next Phase 3 study design for Cylembio with the FDA in December and remain committed to bringing Cylembio to cancer patients seeking alternative treatment options as quickly as possible.
Although the IOB-013 study narrowly missed statistical significance on the primary PFS endpoint, the results of the study support the mechanism of action of our therapeutic cancer vaccines and, we believe, have significantly de-risked the program.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.